to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and anti-TSLP/IL4R bispecific mAb from ...

ATI-052: A preclinical bispecific antibody targeting TSLP and IL4R, expected to enter clinical trials following an IND submission in early 2025. Upcoming milestones include CTTQ’s Phase 2 data ...

- Data from CTTQ’s Phase 2 Studies of Bosakitug (ATI-045) in Chinese Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Expected in the First Half of 2025 to Inform ...

Background: Domestication of wild boars into local and intensive pig breeds has driven adaptive genomic changes, resulting in significant phenotypic differences in intestinal immune function. The ...

Objectives: This study aims to systematically evaluate the efficacy of acupuncture on stroke-associated pneumonia (SAP). Methods: English and Chinese databases were searched from their inception until ...

DimPlot(ueRA,pt.size=1,label=TRUE,label.size = 7)+ ...